Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Carretera de Colmenar Viejo, km 9,100, Madrid, Spain.
Department of Radiology, Hospital Universitario Ramón y Cajal, Madrid and Hospital MD Anderson, Madrid, Spain.
Clin Transl Oncol. 2017 Oct;19(10):1205-1216. doi: 10.1007/s12094-017-1681-7. Epub 2017 Jun 13.
The management of pancreatic ductal adenocarcinoma (PDAC) is a major public health concern worldwide. Currently, most PDAC patients are diagnosed in advanced stages. The signs and symptoms of the disease, except for jaundice, are non-specific. Thus, the current challenge is to identify earlier those individuals for whom specific screening tools and specific treatments would be beneficial. On the basis of the recommendations of the group of experts of multiple medical specialties of the GALLgo Project, the patients with PDAC should be managed by a multidisciplinary team to assess the personal and family history, the best diagnostic and staging procedures and consider all important aspects for treatment decisions. In this article, the group of experts proposes strategies to shorten the diagnosis times in PDAC patients.
胰腺导管腺癌(PDAC)的治疗是全球范围内一个重大的公共卫生关注点。目前,大多数 PDAC 患者被诊断为晚期。除了黄疸之外,该疾病的体征和症状并不具有特异性。因此,目前的挑战是识别出那些能够从特定的筛查工具和特定的治疗中受益的个体。基于 GALLgo 项目多个医学专业专家组的建议,PDAC 患者应由多学科团队进行管理,以评估个人和家族史、最佳的诊断和分期程序,并考虑治疗决策的所有重要方面。在本文中,专家组提出了缩短 PDAC 患者诊断时间的策略。